

Anti-TSLP Reference Antibody (tezepelumab)

Recombinant Antibody Catalog # APR10264

Specification

Anti-TSLP Reference Antibody (tezepelumab) - Product Information

Application FC, Kinetics, Animal Model

Primary Accession
Reactivity
Human
Clonality
Monoclonal
Isotype

Calculated MW 144.6 KDa

Anti-TSLP Reference Antibody (tezepelumab) - Additional Information

Target/Specificity

TSLP

Endotoxin

< 0.001EU/ μg, determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Anti-TSLP Reference Antibody (tezepelumab) - Protein Information

Name TSLP

Function

[Isoform 1]: Cytokine that induces the release of T-cell- attracting chemokines from monocytes and, in particular, enhances the maturation of CD11c(+) dendritic cells. Can induce allergic inflammation by directly activating mast cells.

Cellular Location

Secreted.

Tissue Location

Isoform 1 is expressed in a number of tissues including heart, liver and prostate. Isoform 2 is the predominant form in keratinocytes of oral mucosa, skin and in salivary glands. It is secreted into saliva.




Anti-TSLP Reference Antibody (tezepelumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

Anti-TSLP Reference Antibody (tezepelumab) - Images




Anti-TSLP Reference Antibody (tezepelumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%




The purity of Anti-TSLP Reference Antibody (tezepelumab) is more than 98.64% , determined by SEC-HPLC.






Immobilized human TSLP His at 2 μ g/mL can bind Anti-TSLP Reference Antibody (tezepelumab) \square EC50=0.0518 μ g/mL



Anti-TSLP Reference Antibody (tezepelumab)-induced FACS Blocking activity was evaluated using TSLPR/IL7R-CHO-K. The IC50 was approximately $0.0802 \mu g/mL$.



Tezepelumab reduced levels of IL13 in BALF of OVA asthma model on B-hTSLP/hTSLPR mice. The result showed significant IL13 inhibition effects at 15 mpk.